- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 | 3 | Investing.com | ||
| 12.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | 163 | GlobeNewswire (Europe) | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 08.04. | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.04. | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 3 | Investing.com Deutsch | ||
| 07.04. | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 6 | Investing.com Deutsch | ||
| 07.04. | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| 07.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.03. | Inhibikase Therapeutics GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | 399 | GlobeNewswire (Europe) | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 20.11.25 | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 300 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | 1.001 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 19.08.25 | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 503 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.08.25 | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 345 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 222,50 | -0,22 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| TEVA | 29,200 | -3,95 % | Teva Pharmaceutical Industries Ltd: Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results | Teva-discovered TEV-'408 targets IL-15, a key driver of vitiligo biology TEV-'408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of... ► Artikel lesen | |
| EYEPOINT | 12,300 | 0,00 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,865 | +2,25 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,758 | -3,57 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 07, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 63,38 | -3,41 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| AMARIN | 13,200 | -1,49 % | Amarin Corporation plc: Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape | DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 216,50 | -0,28 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,900 | -8,02 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 488,90 | +2,30 % | Suzhou Ribo Life Science Co., Ltd.: Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH | SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,756 | -3,05 % | XORTX Therapeutics Inc.: XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 68,07 | -0,28 % | BridgeBio Pharma, Inc.: BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches | - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100%... ► Artikel lesen | |
| OPUS GENETICS | 3,580 | +0,56 % | Opus Genetics, Inc.: Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease | Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 37,000 | -0,70 % | Rigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer |
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021
She has resigned from Rigel's Board of... ► Artikel lesen | |
| SAVARA | 5,450 | +0,26 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,49 %) liegt der Kurs bei 2,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.